Illumina Inc (ILMN)

$124.62 -3.62 (-2.82%)
Market Cap 19.61B
Revenue (ttm) 4.34B
Net Income (ttm) 850.00M
EPS (ttm) N/A
PE Ratio 26.59
Forward PE 25.11
Profit Margin 19.57%
Debt to Equity Ratio 0.55
Volume 1,477,700
Avg Vol 2,071,490
Day's Range N/A - N/A
Shares Out 152.90M
Stochastic %K 38%
Beta 1.45
Analysts Sell
Price Target $133.95

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other g...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 858 202 4500
Fax: 858 202 4545
Address:
5200 Illumina Way, San Diego, United States
Estimize
Estimize Mar. 4 at 4:07 PM
Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co
0 · Reply
Streetdilly1
Streetdilly1 Mar. 3 at 12:59 AM
$FLGT why wouldnt illumina $ILMN or revity $RVTY bid $20 and take the other $6 a share in cash for free +get revenues, platform etc for free.
3 · Reply
Nosh
Nosh Feb. 27 at 9:56 PM
$ILMN added.
0 · Reply
notreload_ai
notreload_ai Feb. 27 at 3:17 PM
TD Cowen notes Roche's $150 per genome consumables price for its new Axelios nanopore sequencer came in higher than expected, offering short-term relief to $ILMN market position. https://notreload.xyz/roche-axelios-pricing-gives-illumina-breathing-room/
0 · Reply
Estimize
Estimize Feb. 25 at 5:03 PM
Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 24 at 9:31 PM
$ILMN RSI: 33.95, MACD: -5.6940 Vol: 13.10, MA20: 128.12, MA50: 135.55 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UgoGreg
UgoGreg Feb. 20 at 10:29 PM
$ILMN https://youtu.be/QTb6KRPLkts
0 · Reply
MissionImpossibl
MissionImpossibl Feb. 20 at 3:55 PM
$GRAL $ILMN should go up now !! Good buys at $50 s
0 · Reply
MissionImpossibl
MissionImpossibl Feb. 19 at 11:16 PM
$GRAL $ILMN will do fine ! Just hold long term , will hit back $100 again .
0 · Reply
MissionImpossibl
MissionImpossibl Feb. 19 at 10:44 PM
$GRAL $ILMN Illumina bought GRAIL for ~$8B.REGULATORS blocked it → forced spin. GRAIL IPO’d at ~$25. Today ~ crashed to $55 Market cap 1.5b — still far below the original buy price.
1 · Reply
Latest News on ILMN
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Mar 5, 2026, 9:15 AM EST - 1 day ago

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 11:02 PM EST - 2 days ago

Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Feb 27, 2026, 9:15 AM EST - 7 days ago

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026

Feb 26, 2026, 8:00 AM EST - 8 days ago

Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

Feb 25, 2026, 9:15 AM EST - 9 days ago

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

Illumina launches TruPath Genome, setting a new standard in genomic insight

Feb 24, 2026, 12:15 PM EST - 10 days ago

Illumina launches TruPath Genome, setting a new standard in genomic insight

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

Feb 23, 2026, 9:15 AM EST - 11 days ago

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

Illumina To Webcast Upcoming Investor Conference

Feb 17, 2026, 3:10 PM EST - 17 days ago

Illumina To Webcast Upcoming Investor Conference

Invesco International Growth Fund Q4 2025 Portfolio Update

Feb 16, 2026, 11:43 AM EST - 18 days ago

Invesco International Growth Fund Q4 2025 Portfolio Update

ARGX BABA EPAM RMD SAN

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Feb 5, 2026, 8:14 PM EST - 4 weeks ago

Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

Feb 5, 2026, 4:06 PM EST - 4 weeks ago

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

Feb 3, 2026, 9:15 AM EST - 4 weeks ago

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

Illumina completes acquisition of SomaLogic

Jan 30, 2026, 9:05 AM EST - 5 weeks ago

Illumina completes acquisition of SomaLogic

Illumina Gets Medicare Boost for Cancer Test, Shares Climb

Jan 20, 2026, 1:19 PM EST - 6 weeks ago

Illumina Gets Medicare Boost for Cancer Test, Shares Climb

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

Jan 20, 2026, 9:15 AM EST - 6 weeks ago

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

GRAIL Inc. - Illumina's Divested Holy Grail

Jan 20, 2026, 8:34 AM EST - 6 weeks ago

GRAIL Inc. - Illumina's Divested Holy Grail

GRAL

Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:25 PM EST - 7 weeks ago

Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Illumina unveils dataset to speed up AI-powered drug discovery

Jan 13, 2026, 9:18 AM EST - 7 weeks ago

Illumina unveils dataset to speed up AI-powered drug discovery

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

Jan 13, 2026, 9:15 AM EST - 7 weeks ago

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

Jan 13, 2026, 9:00 AM EST - 7 weeks ago

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

Jan 12, 2026, 4:07 PM EST - 7 weeks ago

Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

Illumina Appoints Dr. Eric Green as Chief Medical Officer

Jan 8, 2026, 4:30 PM EST - 2 months ago

Illumina Appoints Dr. Eric Green as Chief Medical Officer

Illumina and PREMIA partner to expand clinical access to CGP in Asia

Jan 8, 2026, 8:07 AM EST - 2 months ago

Illumina and PREMIA partner to expand clinical access to CGP in Asia

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Jan 6, 2026, 9:15 AM EST - 2 months ago

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Santa Rally Looms: These 5 Stocks Often Deliver Gifts To Investors

Dec 16, 2025, 2:29 PM EST - 2 months ago

Santa Rally Looms: These 5 Stocks Often Deliver Gifts To Investors

CAT FCX GS JPM

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Dec 11, 2025, 9:15 AM EST - 3 months ago

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 19, 2025, 2:23 PM EST - 3 months ago

Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study

Nov 12, 2025, 12:00 PM EST - 4 months ago

Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

Nov 10, 2025, 1:16 PM EST - 4 months ago

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

CSCO FTAI MS

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

Nov 10, 2025, 12:15 PM EST - 4 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

LAB

Illumina Responds to Positive Updates from Chinese Ministry of Commerce

Nov 5, 2025, 5:16 PM EST - 4 months ago

Illumina Responds to Positive Updates from Chinese Ministry of Commerce

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Oct 31, 2025, 12:01 PM EDT - 4 months ago

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 10:26 PM EDT - 4 months ago

Illumina, Inc. (ILMN) Q3 2025 Earnings Call Transcript

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

Oct 30, 2025, 4:05 PM EDT - 4 months ago

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings

Oct 21, 2025, 2:16 PM EDT - 4 months ago

Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

Oct 20, 2025, 4:21 PM EDT - 4 months ago

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

BABA COLB JPM

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

Oct 15, 2025, 9:15 AM EDT - 5 months ago

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

Oct 15, 2025, 9:15 AM EDT - 5 months ago

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

WGS

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Oct 14, 2025, 4:05 PM EDT - 5 months ago

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Illumina launches new business to accelerate technology and data-driven discovery

Oct 1, 2025, 9:05 AM EDT - 5 months ago

Illumina launches new business to accelerate technology and data-driven discovery

ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 5 months ago

ILMN Stock vs. IQV Stock

IQV

Illumina advances personalized cancer care with new pharma development partnerships

Sep 23, 2025, 9:15 AM EDT - 5 months ago

Illumina advances personalized cancer care with new pharma development partnerships

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Sep 18, 2025, 9:15 AM EDT - 6 months ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ALNY

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

Sep 3, 2025, 9:15 AM EDT - 6 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

LAB

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 6 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL IONS MRNA RGEN

Illumina: The Stock Is Still Undervalued

Aug 4, 2025, 4:23 AM EDT - 7 months ago

Illumina: The Stock Is Still Undervalued

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results

Aug 1, 2025, 12:02 PM EDT - 7 months ago

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 1:25 AM EDT - 7 months ago

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

Jul 31, 2025, 4:05 PM EDT - 7 months ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Jul 30, 2025, 9:15 AM EDT - 7 months ago

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Estimize
Estimize Mar. 4 at 4:07 PM
Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co
0 · Reply
Streetdilly1
Streetdilly1 Mar. 3 at 12:59 AM
$FLGT why wouldnt illumina $ILMN or revity $RVTY bid $20 and take the other $6 a share in cash for free +get revenues, platform etc for free.
3 · Reply
Nosh
Nosh Feb. 27 at 9:56 PM
$ILMN added.
0 · Reply
notreload_ai
notreload_ai Feb. 27 at 3:17 PM
TD Cowen notes Roche's $150 per genome consumables price for its new Axelios nanopore sequencer came in higher than expected, offering short-term relief to $ILMN market position. https://notreload.xyz/roche-axelios-pricing-gives-illumina-breathing-room/
0 · Reply
Estimize
Estimize Feb. 25 at 5:03 PM
Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 24 at 9:31 PM
$ILMN RSI: 33.95, MACD: -5.6940 Vol: 13.10, MA20: 128.12, MA50: 135.55 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UgoGreg
UgoGreg Feb. 20 at 10:29 PM
$ILMN https://youtu.be/QTb6KRPLkts
0 · Reply
MissionImpossibl
MissionImpossibl Feb. 20 at 3:55 PM
$GRAL $ILMN should go up now !! Good buys at $50 s
0 · Reply
MissionImpossibl
MissionImpossibl Feb. 19 at 11:16 PM
$GRAL $ILMN will do fine ! Just hold long term , will hit back $100 again .
0 · Reply
MissionImpossibl
MissionImpossibl Feb. 19 at 10:44 PM
$GRAL $ILMN Illumina bought GRAIL for ~$8B.REGULATORS blocked it → forced spin. GRAIL IPO’d at ~$25. Today ~ crashed to $55 Market cap 1.5b — still far below the original buy price.
1 · Reply
100Financial
100Financial Feb. 19 at 12:15 AM
$UBER $ILMN $AMZN $QQQ $SPY All three tickers from yesterday's pick went up 2-3% today. Our top three picks for tomorrow are: UBSR ILMN AMZN All three are identified in a short term bullish pattern. As clarified numerous times, our picks are not for a long term hold. The average hold time is 1-3 days for quick scalping and compounding. GL and happy trading. As always, full trade setups, price targets, trading strategies etc are available to premium members only.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 4:40 AM
$ILMN Current Stock Price: $116.50 Contracts to trade: $115.0 ILMN Feb 20 2026 Call Entry: $2.40 Exit: $3.10 ROI: 29% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 17 at 9:56 PM
$ILMN Share Price: $116.50 Contract Selected: Sep 18, 2026 $115 Calls Buy Zone: $13.34 – $16.48 Target Zone: $23.03 – $28.15 Potential Upside: 63% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 4:20 PM
$ILMN beats Q4 estimates but shares tumble 10.4% — what's spooking investors? 🤔 Despite a 7.4% EPS beat and 5.4% year-over-year revenue growth in Q4, concerns over gross margin contraction are weighing on the stock. 📉 Full breakdown here 👉 https://www.zacks.com/stock/news/2861538/illumina-q4-earnings-revenues-top-estimates-stock-dips?cid=sm-stocktwits-2-2861538-body-33313&ADID=SYND_STOCKTWITS_TWEET_2_2861538_BODY_33313
0 · Reply
ZacksResearch
ZacksResearch Feb. 12 at 3:20 PM
$ILMN crushed Q4… so why did the stock drop 10%? 🤔 The company topped Q4 EPS and revenue estimates and delivered a 42% profit jump, but margin concerns overshadowed the strong print — even with a 2026 growth outlook on the table. ⚠️ Is this a short-term overreaction or a real red flag? Full breakdown here 👉 https://www.zacks.com/stock/news/2861538/illumina-q4-earnings-revenues-top-estimates-stock-dips?cid=sm-stocktwits-2-2861538-teaser-33312&ADID=SYND_STOCKTWITS_TWEET_2_2861538_TEASER_33312
0 · Reply
kb60521
kb60521 Feb. 9 at 9:52 PM
$ILMN Any longtimer here? what are your thoughts and expectations? can you please share...
1 · Reply
kb60521
kb60521 Feb. 9 at 8:49 PM
$ILMN Morning I should have invested in HIMS when I had a choice.....
0 · Reply
medguy
medguy Feb. 9 at 8:17 PM
I'm in $ILMN
0 · Reply
Farorm
Farorm Feb. 9 at 5:28 PM
$ILMN 10 red days in a row is what’s puzzling me.
0 · Reply
kb60521
kb60521 Feb. 9 at 5:16 PM
$ILMN Anyone else seeing 130 EoW???
0 · Reply
SGCoin2
SGCoin2 Feb. 6 at 5:14 PM
$ILMN 🚀⏰ $ILMN
0 · Reply
erpy
erpy Feb. 6 at 4:08 PM
$ILMN For the illiterate that cant read. They destroyed eps estimates. They beat revenues estimates. They gave good guidance. Dont fall for this bearish bullshit share price is showing. Guaranteed recurring revenues, great merger or buyout candidate. LOAD MY BOAT.... just my humble opinion.
1 · Reply